Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas

2019 ◽  
Vol 40 (10) ◽  
pp. 1086-1087 ◽  
Author(s):  
Sandip Basu ◽  
Aadil Adnan
Keyword(s):  
Neuroendocrine Tumours ◽  
Poorly Differentiated ◽  
Well Differentiated ◽  
Grade 3 ◽  
Neuroendocrine Carcinomas

Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms

2011 ◽  
Vol 18 (S1) ◽  
pp. S1-S16 ◽  
Author(s):  
Günter Klöppel
Keyword(s):  
Gastrointestinal Tract ◽  
Neuroendocrine Tumours ◽  
Neuroendocrine Tumour ◽  
Tnm Stage ◽  
Neuroendocrine Neoplasms ◽  
Gastroenteropancreatic Neuroendocrine Neoplasms ◽  
Poorly Differentiated ◽  
Well Differentiated ◽  
Neuroendocrine Carcinomas

Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are composed of cells with a neuroendocrine phenotype. The old and the new WHO classifications distinguish between well-differentiated and poorly differentiated neoplasms. All well-differentiated neoplasms, regardless of whether they behave benignly or develop metastases, will be called neuroendocrine tumours (NETs), and graded G1 (Ki67 <2%) or G2 (Ki67 2–20%). All poorly differentiated neoplasms will be termed neuroendocrine carcinomas (NECs) and graded G3 (Ki67 >20%). To stratify the GEP-NETs and GEP-NECs regarding their prognosis, they are now further classified according to TNM-stage systems that were recently proposed by the European Neuroendocrine Tumour Society (ENETS) and the AJCC/UICC. In the light of these criteria the pathology and biology of the various NETs and NECs of the gastrointestinal tract (including the oesophagus) and the pancreas are reviewed.

scholarly journals 1169P First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade 3 well-differentiated neuroendocrine tumours (NET G3)

2020 ◽  
Vol 31 ◽  
pp. S776
Author(s):  
G. Lamberti ◽  
S. Pusceddu ◽  
T. Ibrahim ◽  
A. Bongiovanni ◽  
R. Berardi ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
First Line ◽  
Net G3 ◽  
Well Differentiated ◽  
Grade 3

CT differentiation of poorly-differentiated gastric neuroendocrine tumours from well-differentiated neuroendocrine tumours and gastric adenocarcinomas

2015 ◽  
Vol 25 (7) ◽  
pp. 1946-1957 ◽  
Author(s):  
Seong Ho Kim ◽  
Se Hyung Kim ◽  
Min-A Kim ◽  
Cheong-il Shin ◽  
Joon Koo Han ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Gastric Adenocarcinomas ◽  
Poorly Differentiated ◽  
Well Differentiated

scholarly journals Endocrine Tumours: Epidemiology of malignant digestive neuroendocrine tumours

2013 ◽  
Vol 168 (4) ◽  
pp. R77-R83 ◽  
Author(s):  
C Lepage ◽  
A M Bouvier ◽  
J Faivre
Keyword(s):  
Neuroendocrine Tumours ◽  
Case Series ◽  
Geographic Region ◽  
Stage At Diagnosis ◽  
Anatomic Site ◽  
Small Hospital ◽  
Diagnosis And Prognosis ◽  
Digestive Cancers ◽  
Poorly Differentiated ◽  
Well Differentiated

Little is known about patients with malignant digestive neuroendocrine tumours (MD-NETs). Although their incidence is increasing, MD-NETs remain a rare cancer, representing 1% of digestive cancers. Most MD-NETs are well-differentiated. MD-NET poorly differentiated carcinomas account for 20% of cases on average. Anatomical localisation of MD-NETs varied according to geographic region. Stage at diagnosis and prognosis for patients with MD-NETs in the general population are considerably worse than often reported from small hospital case series. Prognosis varies with tumour differentiation, anatomic site and histological subtype. There are significant differences in survival from MD-NETs among European countries, independent of other prognostic factors. Early diagnosis is difficult; new therapeutic options appear to represent the best approach to improving prognosis.

Gastric neuroendocrine neoplasms and related precursor lesions

2014 ◽  
Vol 67 (11) ◽  
pp. 938-948 ◽  
Author(s):  
Stefano La Rosa ◽  
Alessandro Vanoli
Keyword(s):  
Neuroendocrine Tumours ◽  
Wide Spectrum ◽  
Clinicopathological Features ◽  
Neuroendocrine Neoplasms ◽  
Precursor Lesions ◽  
Comprehensive Overview ◽  
Ecl Cell ◽  
Poorly Differentiated ◽  
Neuroendocrine Carcinomas

Gastric neuroendocrine neoplasms (NENs) are a heterogeneous group of tumours showing different clinicopathological features and behaviour, implying a wide spectrum of therapeutic options. They are currently classified using the 2010 WHO classification of digestive neuroendocrine neoplasms into G1-neuroendocrine tumours (NETs), G2-NETs, neuroendocrine carcinomas (NECs) and mixed adenoneuroendocrine carcinomas (MANECs). However, most gastric NENs are composed of ECL-cells (ECL-cell NETs) that can be preceded by ECL-cell hyperplastic and dysplastic lesions, whose oncologic potential has not yet been completely elucidated. ECL-cell NETs differ considerably in terms of prognosis depending on the proliferative status and clinicopathological background. The integration of both aspects in the diagnostic pathway may help to better classify tumours in different prognostic categories, especially when diagnosing them in small bioptic specimens. NECs are all poorly differentiated, highly aggressive carcinomas, while MANECs can show different morphological features that are directly associated with different prognoses. Precursor lesions of such carcinomas are not entirely understood. In this review, the clinicopathological features of gastric NENs and related precursor lesions will be described to give the reader a comprehensive overview on this topic.

scholarly journals Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors

Cancers ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 433
Author(s):  
Ugo Marchese ◽  
Martin Gaillard ◽  
Anna Pellat ◽  
Stylianos Tzedakis ◽  
Einas Abou Ali ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Postoperative Morbidity ◽  
Current Data ◽  
Pancreatic Neuroendocrine Tumors ◽  
Tips And Tricks ◽  
Poorly Differentiated ◽  
Well Differentiated ◽  
Multimodal Management ◽  
Neuroendocrine Carcinomas

Pancreatic neuroendocrine tumors (p-NETs) are rare tumors with a recent growing incidence. In the 2017 WHO classification, p-NETs are classified into well-differentiated (i.e., p-NETs grade 1 to 3) and poorly differentiated neuroendocrine carcinomas (i.e., p-NECs). P-NETs G1 and G2 are often non-functioning tumors, of which the prognosis depends on the metastatic status. In the localized setting, p-NETs should be surgically managed, as no benefit for adjuvant chemotherapy has been demonstrated. Parenchymal sparing resection, including both duodenum and pancreas, are safe procedures in selected patients with reduced endocrine and exocrine long-term dysfunction. When the p-NET is benign or borderline malignant, this surgical option is associated with low rates of severe postoperative morbidity and in-hospital mortality. This narrative review offers comments, tips, and tricks from reviewing the available literature on these different options in order to clarify their indications. We also sum up the overall current data on p-NETs G1 and G2 management.

Sign in / Sign up

Export Citation Format

Share Document